trial

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

NCTId NCT01397786
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 1,044 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2016-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
1,044 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2011-09
Primary completion
2016-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Investigators

1
Aleksandar Skuban, M.D.Study Director

Sites

0 total

Linked catalysts

1
Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adul — primary completion2016-01

Facts & assertions

4 sourced
Enrollment
1,044
Phase
PHASE3
Primary Completion Date
2016-01
Status
COMPLETED
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Aleksandar Skuban, M.D.
person